Clinical Trials

The purpose of this study is to determine if people with type 1 VWD experience age related increases in VWF levels and what effect this has on bleeding in this population. In order to discover this, the study will examine medical history, blood and genetic tests for VWD and bleeding and collect information about bleeds from the subjects.

This study is being done to look for early indicators in the blood and urine of hypertensive disorders of pregnancy. Specifically, this study will look for differences between gestational hypertension, preeclampsia, HELLP syndrome and normal pregnancy. The following indicators will be studied: specific activated clotting factors (proteins in the blood that help form clots); the enzyme that cleaves clotting factor aggregates (clots); and microparticles (small particles shed from cells) from blood vessel cells, platelets (part of the blood that forms clots) and in the urine. Gestational hypertension refers to a benign form of high blood pressure in pregnancy.  The results ...

The purpose of this study is to assess the decision-making process in women who have Von Willebrand disease,  regarding their attitudes and beliefs about contraception, pregnancy, and assisted reproduction and how these attitudes and beliefs affect choices and the management of bleeding risk during pregnancy.

The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)

The purpose of this study is to learn about how platelets adhere to the blood von Willebrand factor and how known clinical mutations that result in bleeding affect this process. 

The purpose of this study is to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.

The purpose of this study is to compare recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to minimize menorrhagia in women with Type 1 Von Willebrand disease.